DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study

ダウンロード数 : ? 件

この文献の参照には次のURLをご利用ください : https://ir.lib.shimane-u.ac.jp/52674

言語	英語
著者	Miyazaki, Kana Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie Asano, Naoko Department of Molecular Diagnostics, Nagano Prefectural Shinshu Medical Center, Suzaka Yamada, Tomomi Department of Medical Innovation, Osaka University Hospital, Suita Miyawaki, Kohta Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka Sakai, Rika Department of Medical Oncology, Kanagawa Cancer Center, Yokohama Igarashi, Tadahiko Hematology/Oncology Division, Gunma Cancer Center, Ohta Nishikori, Momoko Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto Ohata, Kinya Department of Hematology, Kanazawa University, Kanazawa Sunami, Kazutaka Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama Yoshida, Isao Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama Yamamoto, Go Department of Hematology, Toranomon Hospital, Tokyo Takahashi, Naoki Department of Hematology and Oncology, International Medical Center, Saitama Medical University, Hidaka Okamoto, Masataka Department of Hematology, Fujita Health University School of Medicine, Toyoake Yano, Hiroki Department of Hematology, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi Nishimura, Yuki Clinical Research Support Center, Mie University Hospital, Tsu Tamaru, Satoshi Clinical Research Support Center, Mie University Hospital, Tsu Nishikawa, Masakatsu Clinical Research Support Center, Mie University Hospital, Tsu Izutsu, Koji Department of Hematology, Toranomon Hospital, Tokyo; Department of Hematology, National Cancer Center Hospital, Tokyo Kinoshita Tomohiro Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya 鈴宮淳司 Ohshima Koichi Department of Pathology, Kurume University School of Medicine, Kurume, Japan Kato Koji Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka Katayama Naoyuki Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie Yamaguchi Motoko Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie
掲載誌名	HAEMATOLOGICA
巻	105
号	9
開始ページ	2308
終了ページ	2315
ISSN	0390-6078
発行日	2020-09
DOI	10.3324/haematol.2019.231076
PubMed ID	31649127
出版者	FERRATA STORTI FOUNDATION
資料タイプ	学術雑誌論文
部局	医学部
備考	This study was supported by grants-in-aid from the Japan Agency for Medical Research and Development, AMED (the Practical Research for Innovative Cancer Control; JP15Ack0106157, JP16ck0106157, JP17ck0106157, JP18ck0106439), the Ministry of Labour, Health, and Welfare of Japan (201438142A), the director of Mie University Hospital (2012, 2013), and the National Cancer Center Research and Development Fund (26-A-4, 29-A-3).